Royal Bank of Canada’s Mersana Therapeutics MRSN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-168
| Closed | -$5K | – | 7472 |
|
|
2025
Q4 | $5K | Sell |
168
-524
| -76% | -$9.95K | ﹤0.01% | 6719 |
|
|
2025
Q3 | $5K | Buy |
692
+686
| +11,433% | +$5.15K | ﹤0.01% | 6705 |
|
|
2025
Q2 | $0 | Sell |
6
-59
| -91% | -$518 | ﹤0.01% | 7222 |
|
|
2025
Q1 | $0 | Sell |
65
-295
| -82% | -$4.55K | ﹤0.01% | 7086 |
|
|
2024
Q4 | $12K | Sell |
360
-98
| -21% | -$5.07K | ﹤0.01% | 6294 |
|
|
2024
Q3 | $22K | Buy |
458
+31
| +7% | +$1.37K | ﹤0.01% | 6072 |
|
|
2024
Q2 | $21K | Buy |
427
+325
| +319% | +$23.5K | ﹤0.01% | 6057 |
|
|
2024
Q1 | $11K | Sell |
102
-1,293
| -93% | -$129K | ﹤0.01% | 6171 |
|
|
2023
Q4 | $81K | Buy |
1,395
+798
| +134% | +$32.1K | ﹤0.01% | 5739 |
|
|
2023
Q3 | $19K | Buy |
597
+82
| +16% | +$3.9K | ﹤0.01% | 6203 |
|
|
2023
Q2 | $42K | Buy |
515
+306
| +146% | +$44.8K | ﹤0.01% | 5858 |
|
|
2023
Q1 | $21K | Sell |
209
-318
| -60% | -$44.6K | ﹤0.01% | 6012 |
|
|
2022
Q4 | $76K | Buy |
527
+415
| +371% | +$70.1K | ﹤0.01% | 5645 |
|
|
2022
Q3 | $18K | Buy |
112
+92
| +460% | +$15K | ﹤0.01% | 6189 |
|
|
2022
Q2 | $2K | Sell |
20
-156
| -89% | -$14.7K | ﹤0.01% | 6972 |
|
|
2022
Q1 | $18K | Sell |
176
-428
| -71% | -$50K | ﹤0.01% | 6657 |
|
|
2021
Q4 | $94K | Buy |
604
+326
| +117% | +$63.4K | ﹤0.01% | 5994 |
|
|
2021
Q3 | $66K | Buy |
278
+89
| +47% | +$26K | ﹤0.01% | 5992 |
|
|
2021
Q2 | $64K | Buy |
189
+29
| +18% | +$11K | ﹤0.01% | 5869 |
|
|
2021
Q1 | $65K | Buy |
160
+143
| +841% | +$69.4K | ﹤0.01% | 5724 |
|
|
2020
Q4 | $11K | Buy |
17
+13
| +325% | +$7.23K | ﹤0.01% | 6335 |
|
|
2020
Q3 | $2K | Hold |
4
| – | – | ﹤0.01% | 6326 |
|
|
2020
Q2 | $3K | Sell |
4
-2
| -33% | -$683 | ﹤0.01% | 6193 |
|
|
2020
Q1 | $1K | Sell |
6
-125
| -95% | -$21.8K | ﹤0.01% | 6463 |
|
|
2019
Q4 | $19K | Buy |
131
+106
| +424% | +$7.75K | ﹤0.01% | 5871 |
|
|
2019
Q3 | $1K | Sell |
25
-38
| -60% | -$2.76K | ﹤0.01% | 6482 |
|
|
2019
Q2 | $6K | Buy |
+63
| New | +$7.42K | ﹤0.01% | 6237 |
|
|
2018
Q4 | – | Sell |
-10
| Closed | -$2K | – | 6981 |
|
|
2018
Q3 | $2K | Buy |
10
+4
| +67% | +$1.34K | ﹤0.01% | 6524 |
|
|
2018
Q2 | $3K | Buy |
+6
| New | +$2.63K | ﹤0.01% | 6167 |
|
|
2018
Q1 | – | Sell |
-2
| Closed | -$1K | – | 6628 |
|
|
2017
Q4 | $1K | Sell |
2
-12
| -86% | -$5.23K | ﹤0.01% | 6401 |
|
|
2017
Q3 | $6K | Buy |
+14
| New | +$5.52K | ﹤0.01% | 6394 |
|
Other funds holding MRSN
Royal Bank of Canada's MRSN Position: Q1 2026 in Review
Royal Bank of Canada sold out of Mersana Therapeutics (MRSN) in Q1 2026, closing a stake of 168 shares — an estimated $5K sold.
Royal Bank of Canada first reported a position in MRSN in Q3 2017 and held it in 31 quarters. The position peaked at $94K in Q4 2021. 1 fund tracked by Wall St. Rank holds MRSN as of Q1 2026.
- Royal Bank of Canada reported no remaining Mersana Therapeutics position as of Q1 2026 after selling out during the quarter.
- Royal Bank of Canada sold 168 Mersana Therapeutics shares in Q1 2026, an estimated $5K.
- Royal Bank of Canada first reported a position in Mersana Therapeutics in Q3 2017 and held it in 31 quarters.
- Royal Bank of Canada's Mersana Therapeutics position peaked at $94K in Q4 2021.
- 1 fund tracked by Wall St. Rank held Mersana Therapeutics as of Q1 2026.
Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.